PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent end Trademerk Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons ere required to respond to a collection of information unless if displays e velid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Novel Pharmaceutical Forms, and Methods of Making and Using the Same		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
I	The attached application, or		
	Application No. PCT/US2005/009305 , filed on MARCH 17, 2005		
	as amended on(if applicable);		
1/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
I/we have re amendmen	I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAMI	E OF INVENTOR(S)		
	e: MAGALI BOURGHOL HICKEY		
Signature:	Vho 0		
Inventor two	D: MATTHEW PETERSON		
Signature:	Metth Gefers Citizen of: UNITED STATES		
Inventor thr	ee: ORN-ALMARSSON /		
Signature:	Citizen of: ICELAND		
Inventor fou	ir: MICHAEL J. ZAWOROTKO		
Signature: _	Citizen of: UNITED STATES		
✓ Additi	ional inventors or a legal representative are being named on 1 (one) additional form(s) attached bereto		

Additional inventors or a legal representative are being named on additional form(s) attached hereto. Additional inventors of a legal representative are being named on (One) additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 end 37 CFR 1.63. The informetion is required to obtein or retein e benefit by the public which is to file (and by the USPTO to process) an application. Confidentielity is governed by 35 U.S.C. 122 end 37 CFR 1.11 end 1.14. This collection is estimated to take 1 minute to complete, including gathering, prepering, and submitting the completed epplication form to the USPTO. Time will vary depending upon the individual case. Any comments on the emount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent end Tredemerk Office, U.S. Depertment of Commerce, P.O. Box 1450, Alexendria, VA 22313-1450, DO NOT SENO FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrie, VA 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Novel Pharmaceutical Forms, and Methods of Making and Using	he Same	
As the below	low named inventor(s), I/we declare that:		
This declara	aration is directed to:		
	The attached application, or		
	Application No. <u>PCT/US2005/009305</u> , filed on <u>MARCH 17, 2005</u>	· · · · · · · · · · · · · · · · · · ·	
	as amended on	(if applicable);	
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;			
I/we have re amendment	I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
ETILL KLAMI	ME OF INVENTOR(S)		
	ve: TANISE SHATTOCK		
	:Citizen of:		
Inventor six	ix: JULIUS REMENAR		
Signature:	Citizen of: UNITED:	STATES	
Inventor sev	even: MARK TAWA		
Signature:	: Warl TarneCitizen of: UNITED !	STATES	
Inventor eig	ight:	•	
Signature: _	Citizen of:		
Additi	ditional inventors or a legal representative are being named on	form(s) attached horate	

Additional inventions of a legal representative are being named on additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complate, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon that individual case. Any commants on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commarce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Novel Pharmaceutical Forms, and Methods of Making and Using the Same		
As the belo	w named inventor(s), I/we declare that:		
This declar	This declaration is directed to:		
	The attached application, or		
	Application No. PCT/US2005/009305 , filed on MARCH 17, 2005		
	as amended on(if applicable);		
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;			
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAM	E OF INVENTOR(S)		
	e: MAGALI BOURGHOL HICKEY		
	Citizen of: UNITED STATES		
Inventor tw	D: MATTHEW PETERSON		
Signature:	Citizen of: UNITED STATES		
Inventor the	ee: ORN ALMARSSON		
Signature:	Citizen of: ICELAND		
Inventor for	ur: MICHAEL J. ZAWOROTKO		
Signature:	Citizen of: UNITED STATES TO WGO 6 M		
✓ Addi	tional inventors or a legal representative are being named on1 (one)additional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Pagerwork Reduction Act of 1995, no gersons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	Novel Pharmaceutical Forms, and Methods of Making and Using the Same		
MACHROH			
As the belo	w named inventor(s), I/we declare that:		
This declar	This declaration is directed to:		
	The attached application, or		
	Application No. PCT/US2005/009305 , filed on MARCH 17, 2005		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAM	E OF INVENTOR(S)		
Inventor fiv	e: TANISE SHATTOCK		
Signature:	Citizen of:		
Inventor six	C: JULIUS REMENAR		
Signature:	Citizen of: UNITED STATES		
Inventor se	ven: MARK TAWA		
Signature:	Citizen of: UNITED STATES		
Inventor ei	ght:		
Signature:	Citizen of:		
Addi	tional inventors or a legal representative are being named onadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETEO FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid QMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Novel Pharmaceutical Forms, and Methods of Making and Using the Same	
As the belo	w named inventor(s), I/we declare that:	
This declara	ation is directed to:	
	The attached application, or	
	Application No. PCT/US2005/009305 , filed on MARCH 17, 2005 ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
CIIII NIAM	E OF INVENTOR(S)	
	e: MAGALI BOURGHOL HICKEY	
	Citizen of: UNITED STATES	
Inventor two	D: MATTHEW PETERSON	
Signature:	Citizen of: UNITED STATES	
Inventor thr	ee: ORN ALMARSSON	
Signature:	Citizen of: _ICELAND	
Inventor for	ir: MICHAEL J. ZAWOROTKO	
Signature:	Citizen of:	
√ Addit	ional inventors or a legal representative are being named on 1 (one) additional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless if displays a valid OMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of	Novel Pharmaceutical Forms, and Methods of Making and Using the Same		
MACHRION			
As the belo	w named inventor(s), I/we declare that:		
This declar	This declaration is directed to:		
	The attached application, or		
	Application No. PCT/US2005/009305 , filed on MARCH 17, 2005		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
	E OF INVENTOR(S)		
Inventor fiv Signature:	e: TANISE SHATTOCK Citizen of: JAMAICA		
-			
	CHITCH OF LIMITED STATES		
Signature:	Citizen of: UNITED STATES		
Inventor se	ven: MARK TAWA		
Signature:	Citizen of: UNITED STATES		
Inventor ei	ght:		
Signature:	Citizen of:		
Addi Addi	tional inventors or a legal representative are being named onadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63 representative are being framed on additional invertors of a legal representative are being framed on additional invertors. This collection is required by 35 U.S.C. 115 and 37 CFR 1.63 required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.